Physician profile
Nikky Keer
NPI 1053751651
$7,342.31
in general payments reported to CMS, 2019-2025
18 companies · $5,897 in 2025
The $5,897 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2021: $23.05 · 2022: $265 · 2024: $885 · 2025: $5,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $1,270 · Food and Beverage: $811 · Honoraria: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $1,270.46 |
| Food and Beverage | $810.91 |
| Honoraria | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,334.67 | 2025 | |
| Cook Incorporated | $700.00 | 2024 | |
| United Therapeutics Corporation | $272.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.55 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $197.34 | 2019-2025 | Nucala |
| Inspire Medical Systems, INC. | $160.37 | 2025 | Inspire |
| Genzyme Corporation | $152.08 | 2022-2025 | |
| Invivyd INC | $58.83 | 2025 | Pemgarda |
| Edwards Lifesciences Corporation | $55.84 | 2022-2024 | Hemosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.86 | 2025 | Ofev |
| Becton, Dickinson and Company | $30.84 | 2024 | Hemosphere |
| Esperion Therapeutics, INC. | $24.11 | 2025 | Nexletol |
| Zoll Respicardia, INC. | $23.13 | 2024 | Remede System |
| Abbvie INC. | $22.63 | 2024 | |
| Liquidia Technologies, INC. | $21.35 | 2025 | Yutrepia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $21.08 | 2025 | Tremfya |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.89 | 2019 | |
| Lilly USA, LLC | $14.12 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikky Keer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.